Tessera

Amy Pomeroy

@amypomeroy.bsky.social

computational cancer pharmacologist at UNC | modeling clinical trials of combination therapy

acpalmer.bsky.social @acpalmer.bsky.social · last yr.

New paper, with Amy Pomeroy! A model of intratumor and interpatient heterogeneity explains clinical trials of curative combination therapy for lymphoma now out in Blood Cancer Discovery: doi.org/10.1158/2643... #mathonc #lymsm #BloodCancer 1/n

A model of intra-tumor and inter-patient heterogeneity explains clinical trials of curative combination therapy for lymphoma

Abstract. Models of tumor drug response have illuminated important concepts in oncology, but there remains a need for theory that combines intra-tumor and inter-patient heterogeneity to explain patien...

doi.org

Amy Pomeroy @amypomeroy.bsky.social · last yr.

I am so excited to share that our new paper is out! A model of intratumor and interpatient heterogeneity explains clinical trials of curative combination therapy for lymphoma Out in Blood Cancer Discovery doi.org/10.1158/2643-3230.BCD-24-0230 #mathonc #lymsm #BloodCancer 1/n

A model of intra-tumor and inter-patient heterogeneity explains clinical trials of curative combination therapy for lymphoma

doi.org

Association for Cancer Systems Biologists @cancersysbio.bsky.social · 2y ago

An impressive result from their work - their model would have been able to predict from single treatment trials what would have happened in the combination trials

Association for Cancer Systems Biologists @cancersysbio.bsky.social · 2y ago

Dr. Amy Pomeroy is up next in our postdoc spotlight session telling us about their work on mechanistic modeling of combination therapy doi.org/10.1101/2024...